cagrilintide results Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study Eloralintide vs. Cagrilintide vs. Petrelintide
Eloralintide vs. Cagrilintide vs. Petrelintide In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Subcutaneous Cagrilintide, Semaglutide Shows Significant Weight Loss in Type 2 Diabetes Trial Pharmacy Times Cagrilintide Peptide Dosing Guide: Titration, Schedule & Safety (2026) Trial Scorecard: REDEFINE 1 and 2 Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet
Pay in 4 interest-free payments of $7.22 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9





01163-7/asset/e2dcb6d3-462b-4d65-88e0-ea3cc5eaf66c/main.assets/gr3_lrg.jpg)